pi 083 has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berndt, N; Guida, WC; Kazi, A; Lawrence, H; McLaughlin, ML; Sebti, SM; Springett, GM; Yip, RM | 1 |
| Grant, S | 1 |
2 other study(ies) available for pi 083 and Neoplasms
| Article | Year |
|---|---|
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chymotrypsin; Cyclin-Dependent Kinase Inhibitor p27; Drug Discovery; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neoplasms; Proteasome Inhibitors; Protein Conformation; Pyrazines; Serine Proteinase Inhibitors; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2009 |
Selectively killing transformed cells through proteasome inhibition.
Topics: Anthracyclines; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Transformation, Neoplastic; Humans; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitination | 2009 |